Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sNSE:SAIPARENT +5.28%14 3-Year RORE % is 0.00 as of Sep. 2025. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 947 Drug Manufacturers companies, Sai Parenteral's ranks worse than 105596.52% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Sai Parenteral's does not have enough data to calculate 3-Year RORE %.
Sai Parenteral's (NSE:SAIPARENT) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Sai Parenteral's 3-Year RORE % Related Terms
Sai Parenteral's 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's 3-Year RORE % Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
3-Year RORE %
0.00
0.00
0.00
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
3-Year RORE %
0.00
0.00
0.00
0.00
NSE:SAIPARENT vs LLY, JNJ, ABBV: 3-Year RORE % Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2025 and 3-year before.
Sai Parenteral's (NSE:SAIPARENT) has a 3-Year RORE % of 0.00 as of Sep. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sai Parenteral's and its competitors. According to the industry distribution chart, Sai Parenteral's ranks #999999 out of 947 companies in the Drug Manufacturers industry.
Is Sai Parenteral's' 3-Year RORE % too high?
Sai Parenteral's' current 3-Year RORE % is 0.00. Based on the distribution chart, Sai Parenteral's ranks #999999 out of 947 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' 3-Year RORE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #999999 out of 947 companies for 3-Year RORE %. This places Sai Parenteral's in the lower half of its industry. The industry median 3-Year RORE % is 2.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 2.78, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current 3-Year RORE % is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
